JIANGSU LANFENG BIO-CHEMICAL CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.28 CNY | -0.23% |
|
-7.96% | -38.15% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 2,211 | 2,418 | 1,347 | 1,697 | 1,933 | 2,588 |
| Enterprise Value (EV) 1 | 2,445 | 2,648 | 1,333 | 1,710 | 2,028 | 2,743 |
| P/E ratio | -2.53 x | -4.68 x | 99 x | -3.47 x | -6.03 x | -7.77 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 1.49 x | 1.61 x | 1 x | 1.18 x | 1.34 x | 1.49 x |
| EV / Revenue | 1.65 x | 1.76 x | 0.99 x | 1.18 x | 1.4 x | 1.57 x |
| EV / EBITDA | 207 x | -215 x | 13.4 x | -15.6 x | -23.4 x | -22.8 x |
| EV / FCF | 6.62 x | 20.4 x | -7.1 x | 48.4 x | 41 x | 25.6 x |
| FCF Yield | 15.1% | 4.9% | -14.1% | 2.07% | 2.44% | 3.91% |
| Price to Book | 1.33 x | 2.13 x | 1.16 x | 2.55 x | 7.02 x | 102 x |
| Nbr of stocks (in thousands) | 340,086 | 340,086 | 340,086 | 340,086 | 373,936 | 373,936 |
| Reference price 2 | 6.500 | 7.110 | 3.960 | 4.990 | 5.170 | 6.920 |
| Announcement Date | 4/15/19 | 4/27/20 | 4/19/21 | 4/15/22 | 4/26/23 | 4/29/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1,481 | 1,504 | 1,342 | 1,444 | 1,445 | 1,742 |
| EBITDA 1 | 11.81 | -12.32 | 99.58 | -109.7 | -86.74 | -120.2 |
| EBIT 1 | -147.2 | -155.1 | -24.27 | -223.8 | -179.8 | -218 |
| Operating Margin | -9.94% | -10.31% | -1.81% | -15.5% | -12.44% | -12.52% |
| Earnings before Tax (EBT) 1 | -921.6 | -559.8 | 2.77 | -538.9 | -247 | -354.3 |
| Net income 1 | -875 | -516.6 | 14.82 | -491.2 | -320.7 | -332.3 |
| Net margin | -59.06% | -34.34% | 1.1% | -34.02% | -22.19% | -19.08% |
| EPS 2 | -2.570 | -1.520 | 0.0400 | -1.440 | -0.8576 | -0.8911 |
| Free Cash Flow 1 | 369.4 | 129.9 | -187.7 | 35.34 | 49.48 | 107.1 |
| FCF margin | 24.94% | 8.63% | -13.99% | 2.45% | 3.42% | 6.15% |
| FCF Conversion (EBITDA) | 3,128.7% | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/15/19 | 4/27/20 | 4/19/21 | 4/15/22 | 4/26/23 | 4/29/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 235 | 230 | - | 13.1 | 94.4 | 155 |
| Net Cash position 1 | - | - | 13.7 | - | - | - |
| Leverage (Debt/EBITDA) | 19.88 x | -18.7 x | - | -0.1191 x | -1.088 x | -1.288 x |
| Free Cash Flow 1 | 369 | 130 | -188 | 35.3 | 49.5 | 107 |
| ROE (net income / shareholders' equity) | -41.8% | -37% | 1.29% | -53.8% | -62.6% | -114% |
| ROA (Net income/ Total Assets) | -2.43% | -3.11% | -0.61% | -6.93% | -7.02% | -5.59% |
| Assets 1 | 35,946 | 16,596 | -2,450 | 7,091 | 4,570 | 5,945 |
| Book Value Per Share 2 | 4.870 | 3.340 | 3.410 | 1.960 | 0.7400 | 0.0700 |
| Cash Flow per Share 2 | 1.710 | 0.8200 | 0.9700 | 0.2500 | 0.0500 | 1.240 |
| Capex 1 | 118 | 91.9 | 108 | 88.9 | 31.1 | 468 |
| Capex / Sales | 7.97% | 6.11% | 8.03% | 6.16% | 2.15% | 26.89% |
| Announcement Date | 4/15/19 | 4/27/20 | 4/19/21 | 4/15/22 | 4/26/23 | 4/29/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -38.15% | 222M | |
| +1.62% | 3.61B | |
| -20.29% | 2.15B | |
| -8.65% | 1.95B | |
| +3.79% | 1.9B | |
| +0.11% | 1.71B | |
| -3.83% | 1.3B | |
| +3.87% | 1.19B | |
| -19.88% | 1.06B | |
| +1.78% | 1.06B |
- Stock Market
- Equities
- 002513 Stock
- Financials Jiangsu Lanfeng Bio-chemical Co.,Ltd
